Table 1.
Patients’ baseline characteristics.
| Responder (n = 19) | Non-Responder (n = 6) | |
|---|---|---|
| Age | 52.1 ± 13.1 | 54.0 ± 15.1 |
| Gender (M/F) | 8/11 | 2/4 |
| Body mass index | 23.6 ± 3.8 | 21.3 ± 3.6 |
| NSAIDs intolerance | 8 | 2 |
| EOM * | 4 | 5 |
| Smoking history (never/ex) | 13/6 | 4/2 |
| ESS history (Y/N) | 17/2 | 6/0 |
| Total IgE (IU/mL) | 429 ± 403 | 401 ± 275 |
| Positive RAST (single/multi) | 2/17 | 1/5 |
| Eosinophils (/μL) [peak value] | 466 ± 287 [699 ± 328] | 741 ± 495 [1022 ± 457] |
| FENO (ppb) | 65.2 ± 67.6 | 75.8 ± 42.4 |
| Lund-Mackay scale | 16.0 ± 4.5 | 15.3 ± 4.8 |
| Polyp score | 4.6 ± 1.6 | 4.7 ± 2.0 |
| JESREC score | 15.1 ± 1.7 | 16.7 ± 0.8 |
| Impaired sense of smell | 13 | 5 |
| FEV1%pred. | 82.6 ± 18.2 | 77.6 ± 22.7 |
| FEF25–75%pred. | 55.5 ± 30.4 | 48.3 ± 25.9 |
| FVC %pred. | 93.9 ± 15.8 | 96.0 ± 11.8 |
| Asthma Control Test | 21.3 ± 3.3 | 20.7 ± 5.1 |
| Asthma exacerbation (per year) ** | 1.4 ± 1.5 | 1.2 ± 0.4 |
| Treatment | ||
| Inhaled corticosteroids (μg) *** | 1200 ± 330 | 1133 ± 350 |
| LABA | 19 | 6 |
| LAMA | 5 | 1 |
| LTRA | 16 | 4 |
| Theophylline | 3 | 1 |
| Anti-histamine | 7 | 3 |
| Inhaled nasal corticosteroids | 12 | 3 |
| Oral corticosteroids | 2 | 0 |
| Omalizumab (mg) (per month) | 426 ± 251 | 425 ± 148 |
EOM = eosinophilic otitis media; ESS = endoscopic sinus surgery; FENO = fractionated exhaled nitrogen oxide; FEV1 = forced expiratory volume in 1 s; FEF25–75 = forced expiratory flow between 25% and 75% of vital capacity; FVC = forced vital capacity; JESREC = Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis; LABA = long-acting β2-agonist; LAMA = long-acting muscarinic antagonist; LTRA = leukotriene receptor antagonist; RAST = radioallergosorbent test’ * p < 0.05 (Fisher’s exact test); ** clinically significant exacerbation, defined as any worsening of asthma considered by the treating physician to require systemic corticosteroids; *** equivalent doses of fluticasone propionate. Values are number of subjects and mean ± standard deviation.